Shore Capital reaffirmed their buy rating on shares of GSK (LON:GSK – Get Rating) in a report released on Monday morning, MarketBeat.com reports.
Other equities analysts have also recently issued research reports about the company. Jefferies Financial Group set a GBX 1,575 ($19.73) price target on GSK in a report on Wednesday, February 1st. Berenberg Bank restated a buy rating and set a GBX 1,730 ($21.67) price target on shares of GSK in a report on Wednesday, April 19th. Credit Suisse Group restated a neutral rating and set a GBX 1,510 ($18.92) price target on shares of GSK in a report on Thursday, February 2nd. Barclays restated an equal weight rating and set a GBX 1,450 ($18.16) price target on shares of GSK in a report on Thursday, April 27th. Finally, The Goldman Sachs Group set a GBX 2,000 ($25.05) target price on GSK in a report on Monday, March 6th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of Hold and an average price target of GBX 1,573.33 ($19.71).
GSK Stock Up 0.1 %
Shares of GSK opened at GBX 1,471 ($18.43) on Monday. The business’s 50 day moving average is GBX 1,451.57 and its 200 day moving average is GBX 1,437.65. The company has a market capitalization of £59.58 billion, a PE ratio of 1,348.26, a price-to-earnings-growth ratio of 2.04 and a beta of 0.28. GSK has a 12-month low of GBX 1,280.92 ($16.05) and a 12-month high of GBX 2,280.50 ($28.57). The company has a current ratio of 0.95, a quick ratio of 0.73 and a debt-to-equity ratio of 184.80.
GSK Increases Dividend
The firm also recently disclosed a dividend, which will be paid on Thursday, July 13th. Investors of record on Thursday, May 18th will be issued a dividend of GBX 14 ($0.18) per share. The ex-dividend date of this dividend is Thursday, May 18th. This represents a yield of 0.93%. This is a boost from GSK’s previous dividend of $13.75. GSK’s payout ratio is presently 5,137.61%.
Insider Buying and Selling at GSK
In other news, insider Jonathan Symonds bought 2,100 shares of the firm’s stock in a transaction on Monday, March 20th. The stock was acquired at an average cost of GBX 1,399 ($17.52) per share, with a total value of £29,379 ($36,801.95). In other news, insider Jonathan Symonds bought 2,100 shares of the firm’s stock in a transaction on Monday, March 20th. The stock was acquired at an average cost of GBX 1,399 ($17.52) per share, with a total value of £29,379 ($36,801.95). Also, insider Iain Mackay purchased 200 shares of GSK stock in a transaction dated Tuesday, April 18th. The stock was bought at an average cost of GBX 1,493 ($18.70) per share, with a total value of £2,986 ($3,740.45). Insiders bought a total of 2,309 shares of company stock valued at $3,249,586 in the last ninety days. Corporate insiders own 1.75% of the company’s stock.
About GSK
(Get Rating)
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Further Reading
Receive News & Ratings for GSK Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GSK and related companies with MarketBeat.com’s FREE daily email newsletter.